ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

BNT3211

A development code.

Its studies are led by BioNTech.

Furthest: phase 2, since Nov 16, 20261 company-led study, 1 open or runningNext primary completion: Oct 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioNTech11 open or runningphase 2since Nov 16, 2026Nov 16, 2026Oct 2029phase 2 · NCT07951359

Also a collaborator on its studies: BioNTech (Shanghai) Pharmaceuticals.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 16, 2026First study: phase 2 study in Advanced Solid TumorFirst studyNCT07951359 · 345 planned

Ahead

  1. Oct 2029Primary completion: phase 2 study in Advanced Solid TumorNCT07951359

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07951359Advanced Solid Tumor2Not yet recruitingOct 2029345

How it is read

Names in the registry

  • “BNT3211”, 1 entry

Codes read as this program: BNT3211.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 21, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.